Anastrozole 1 - Ice Pharmaceuticals

The introduction of anastrozole by Zeneca in 1995 marked a significant advancement in anti-estrogenic therapy. As the first widely adopted aromatase inhibitor, it halted estrogen synthesis at the enzymatic level, making it especially useful for postmenopausal patients. It rose to global prominence following the success of the ATAC study, which showed better disease-free survival than tamoxifen. The trial’s data, published in 2002, played a decisive role in shaping hormonal treatment protocols.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrozole 1 by Ice Pharmaceuticals, consult with your doctor or healthcare professional.